All Updates

All Updates

icon
Filter
Product updates
GeneDx announces patient access program for pediatric epilepsy exome sequencing
Precision Medicine
Jun 5, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Precision Medicine

Precision Medicine

Jun 5, 2024

GeneDx announces patient access program for pediatric epilepsy exome sequencing

Product updates

  • GeneDx has initiated a patient access program in association with leading biopharma companies, aiming to enhance access to exome sequencing for pediatric epilepsy patients.

  • To be eligible for the test, patients must meet certain requirements, which include a test ordered by an authorized healthcare provider, as well as being a US citizen of 18 years or below who has experienced an unprovoked seizure under 8 years of age and have no confirmed diagnosis of a neurodevelopmental disorder. 

  • The company asserts that expanded access to exome testing will result in more children receiving a diagnosis and provide better understanding of the relationship between genes and diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.